Pfizer laid off 100 employees in Bothell, Wash., according to a filing with the state Employment Security Department posted ...

The Washington State Employment Security Department has said that 100 workers are affected by Pfizer’s (NYSE:PFE) layoff, ...

Pfizer's diversified pipeline and new product launches are driving operational growth. Click here to read more about PFE ...

Pfizer stock is undervalued with strong non-COVID growth, robust Q2 2025 results, and strategic R&D pivots. See more on PFE ...

Pfizer has urged a Florida federal judge to dismiss lawsuits claiming its birth control shot Depo-Provera can cause users to ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It ...

Operational Growth: The company is seeing a resurgence in operational growth, driven by new product launches and a diversified pipeline. For example, the introduction of innovative treatments in ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

In Q2 2025, Pfizer reported notable revenues from key oncology drugs: The increasing demand for drugs like Padcev and the introduction of new therapies such as Elrexfio, which generated $85 million in ...

Pfizer ( PFE -0.18%) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...